T1	MultiCitation 984 985	6
T2	Context 703 990	Hallmarks of these tumors include a high enrichment for a CD44+/CD24-/low TIC signature, a downregulation of cell junction proteins such as cadherins and claudins, an enrichment in mesenchymal markers, high lymphocyte infiltrations, and high phenotypic resistance to chemotherapy [6,11].
T7	OVERSIMPLIFY 34825 35012	These findings suggest that claudin-low tumors show some chemotherapy sensitivity but overall have a poor prognosis and may not be managed effectively with existing chemotherapy regimens.
